SCHEMBL2654472

SCHEMBL2654472

O=Cc1cccc(C(=O)NCCC(=O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UNG P13051 1/20 0.56
ITGB3 P05106 2/20 0.52
ITGA2B P08514 1/20 0.52
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.46
PRSS1 P07477 1/20 0.46
CTSG P08311 1/20 0.46
CTRB1 P17538 1/20 0.46
CMA1 P23946 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ITGA2 P17301 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9717417 0.85 ITGB3 (0.65) ITGB3ITGA2BLMNASMN1; SMN2PRSS1
SCHEMBL27476441 0.83 UNG (0.53) UNGLMNASMN1; SMN2HDAC3HDAC4
SCHEMBL13733425 0.83 UNG (0.53) UNGSMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL2646800 0.81 CA1 (0.58) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL2646881 0.81 CA1 (0.58) LMNAPRSS1CTSGCTRB1CMA1
SCHEMBL2276760 0.81 HPGD (0.56) UNGLMNASMN1; SMN2LOXL2L3MBTL1
SCHEMBL3197946 0.80 KDM4E (0.59) ITGB3ITGA2BLMNASMN1; SMN2PRSS1
SCHEMBL6184692 0.80 UNG (0.56) UNGSMN1; SMN2HDAC3HDAC1L3MBTL1
SCHEMBL28443239 0.79 NPC1 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15651061 0.79 HDAC6 (0.66) UNGSMN1; SMN2HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585517-A1 USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2005-10-19 EP disclosed
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed
WO-2004062663-A1 USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR UNG 4635/4885ITGB3 1978/4885ITGA2B 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.